Michael Entzeroth
Director de Operaciones en Cennerv Pharmaceuticals Ltd. .
Cargos activos de Michael Entzeroth
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Cennerv Pharmaceuticals Ltd.
Cennerv Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cennerv Pharmaceuticals Ltd. engages in the pharmaceutical development specializing in CNS disorders with an initial focus on mental health such as depression, insomnia, dementia, schizophrenia and autism. The company was founded on July 13, 2015 and is headquartered in Singapore. | Director de Operaciones | - | - |
Director Técnico/Científico/I+D | - | - |
Historial de carrera de Michael Entzeroth
Antiguos cargos conocidos de Michael Entzeroth.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Pharma Resources Asia Pte Ltd. | Director Ejecutivo | 01/11/2006 | 01/12/2014 |
Chakra Biotech Pte Ltd. | Director Técnico/Científico/I+D | 01/02/2014 | 01/12/2014 |
Agency for Science, Technology & Research
Agency for Science, Technology & Research Miscellaneous Commercial ServicesCommercial Services Agency for Science, Technology & Research engages in fostering scientific research and development. It is the agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. The company was founded in 1991 and is headquartered in Singapore. | Corporate Officer/Principal | 01/07/2007 | 01/07/2013 |
EUROFINS CEREP | Corporate Officer/Principal | 01/04/1999 | 01/09/2002 |
Boehringer Ingelheim Pharma GmbH & Co., KG
Boehringer Ingelheim Pharma GmbH & Co., KG BiotechnologyHealth Technology Part of C.H. Boehringer Sohn AG & Co. KG, Boehringer Ingelheim Pharma GmbH & Co. KG is a pharmaceutical company that manufactures pharmaceutical products. The company is based in Ingelheim, Germany. The German company was founded in 1885. The CEO is Sabine Nikolaus. | Corporate Officer/Principal | 01/04/1985 | 01/02/1995 |
S*BIO Pte Ltd.
S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Director Técnico/Científico/I+D | 01/04/2003 | - |
Formación de Michael Entzeroth.
Universität zu Köln | Doctorate Degree |
Estadísticas
Internacional
Singapur | 6 |
Alemania | 3 |
Francia | 2 |
Operativa
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 3 |
Chief Operating Officer | 1 |
Sectorial
Health Technology | 4 |
Commercial Services | 3 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
EUROFINS CEREP | Commercial Services |
Empresas privadas | 6 |
---|---|
Agency for Science, Technology & Research
Agency for Science, Technology & Research Miscellaneous Commercial ServicesCommercial Services Agency for Science, Technology & Research engages in fostering scientific research and development. It is the agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. The company was founded in 1991 and is headquartered in Singapore. | Commercial Services |
S*BIO Pte Ltd.
S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Health Technology |
Boehringer Ingelheim Pharma GmbH & Co., KG
Boehringer Ingelheim Pharma GmbH & Co., KG BiotechnologyHealth Technology Part of C.H. Boehringer Sohn AG & Co. KG, Boehringer Ingelheim Pharma GmbH & Co. KG is a pharmaceutical company that manufactures pharmaceutical products. The company is based in Ingelheim, Germany. The German company was founded in 1885. The CEO is Sabine Nikolaus. | Health Technology |
Chakra Biotech Pte Ltd. | |
Cennerv Pharmaceuticals Ltd.
Cennerv Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cennerv Pharmaceuticals Ltd. engages in the pharmaceutical development specializing in CNS disorders with an initial focus on mental health such as depression, insomnia, dementia, schizophrenia and autism. The company was founded on July 13, 2015 and is headquartered in Singapore. | Health Technology |
Pharma Resources Asia Pte Ltd. |
- Bolsa de valores
- Insiders
- Michael Entzeroth
- Experiencia